BioSpace News Archive

Aruvant Sciences announced management will participate in multiple gene therapy conferences taking place in March.

FineHeart S.A, a preclinical medical device company that has developed the ICOMS FLOWMAKER®, a fully Implantable Cardiac Output Management System designed to address the unmet need of patients suffering from severe heart failure, today announced the grant by the USPTO (United States Patent and Trademark Office) in the United States, of their new patent US 11 097093.

Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, will release its financial results for the fourth quarter and full year ended December 31, 2021, after the market close on Thursday, March 10, 2022.

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the Cowen 42nd Annual Health Care Conference on Wednesday, March 9, 2022 at 2:50 p.m. Eastern Time.

MiNK Therapeutics, announced that it has begun dosing patients with solid tumor cancers with AgenT-797 alone and in combination with approved anti-PD-1 checkpoint inhibitors in a Phase 1 open-label clinical trial.

The Common Shares will be issued in reliance on certain prospectus exemptions available under Canadian securities legislation and will be subject to a four month and one day hold period from the date of issuance.

Graphite Bio Announces Participation in Upcoming Cowen 42nd Annual Health Care Conference.

Pandemic Response Lab (PRL), a wholly-owned subsidiary of Opentrons Labworks, Inc., today announced the launch in its Rockville, Maryland lab of its concise respiratory panel, which simultaneously tests four viruses: SARS-CoV-2, influenza A and B, and respiratory syncytial virus (RSV).

Felix Biotechnology today announced it received a strategic investment from the Cystic Fibrosis Foundation as part of a Therapeutics Development Award.

AIM ImmunoTech Inc., an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, announced the appointment of Robert Dickey IV, as its Chief Financial Officer.